Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Global executive survey: Mobile health technologies

Doctors (per 1,000 people) in 2015

Top ten countries with the highest population in 2020

Social media use in healthcare worldwide

Global healthcare spending

Old problems, fresh solutions

Connect to care

Key Findings

By many comparative measures South Korea has an enviable healthcare system: one that covers the entire population, is relatively cheap to run (healthcare spending is around 7% of GDP, far lower than in many comparably wealthy economies) and gives patients access to a broad range of specialist advice and state-of-the-art treatments. Yet the sustainability of the system, funded in part by mandatory national insurance contributions and in part through patient co-payments, is far from assured.

Patient Engagement

From population growth to the uptake of social media in healthcare, major economic and tech trends are changing the way healthcare providers engage with patients. Through a series of infographics, sponsored by KPMG, the EIU showcases key country, forecast and survey data on the following themes:

Fixing healthcare

Our research drew on two main initiatives:

  • In December 2008 and January 2009, we conducted a global survey of healthcare professionals and life science industry executives in four key economies: the US, UK, Germany and India. In total, 775 respondents took part in the survey, representing a variety of roles within the healthcare sector.
  • To supplement the survey results, we also conducted in-depth interviews with numerous leading figures in the healthcare sector.

Risk Management in the Pharmaceuticals and Life Sciences Industry

In August 2009, the Economist Intelligence Unit conducted a global survey of executives in the pharmaceutical and life sciences industry on how risk is managed in their organisations. The 65 responses were compared with those of a June 2009 global survey of 353 executives in a broad range of other industries. Of the pharmaceutical and life sciences respondents, nearly half (46%) are C-level executives and the remainder are other senior executives and managers. Sixty-eight percent represent companies with annual global revenues above US$500m.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week